Shandong Weigao Blood Purification Products Co., Ltd, a dominant player in China’s blood purification sector, has submitted an initial public offering (IPO) application to the Shanghai Stock Exchange (SSE). The exchange has accepted the filing for review, with the company eyeing a substantial capital injection of RMB 1.351 billion (USD 190 million).
Weigao Blood Purification, known for its leadership in the blood dialyzer and blood dialysis tubing markets within China, reported revenues of RMB 3.426 billion and net profits of RMB 229 million for the year 2023. The proceeds from the IPO are expected to bolster the company’s financial position and support its continued growth in the medical device industry.- Flcube.com
